NCT04822649 Exercise Capacity According to Coronary Microvascular Dysfunction and Body Composition
| NCT ID | NCT04822649 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Korea University Anam Hospital |
| Condition | Heart Failure With Preserved Ejection Fraction (HFpEF) |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2021-04-15 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2021-04-15 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The correlation of coronary microvascular function and body composition with cardiopulmonary exercise capacity will be assessed in patients with heart failure with preserved ejection fraction.
Eligibility Criteria
Inclusion Criteria: * Age 20 to 80 * Typical/atypical chest pain or ischemic symptoms including dyspnea * No significant coronary artery stenosis (\>50% stenosis) in coronary angiography or computed tomography * Left ventricular ejection fraction ≥50% Exclusion Criteria: * More than moderate valvular heart disease * Congenital heart disease * Chronic renal failure (estimated glomerular filtration rate \<30 ml/min/1.73m2) or end-stage renal failure undergoing hemodialysis or peritoneal dialysis * Asthma, chronic obstructive pulmonary disease and primary pulmonary hypertension * Receiving anticancer drugs * Vasculitis associated with autoimmune diseases * Patients with difficulty in performing exercise load evaluation (treadmill, bicycle ergometer) * Atrial fibrillation * Atrioventricular block with more than second degrees, symptomatic bradycardia, cryo-node failure syndrome, Wolff-Parkinson-White (WPW) patients
Contact & Investigator
Frequently Asked Questions
Who can join the NCT04822649 clinical trial?
This trial is open to participants of all sexes, aged 20 Years or older, up to 80 Years, studying Heart Failure With Preserved Ejection Fraction (HFpEF). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04822649 currently recruiting?
Yes, NCT04822649 is actively recruiting participants. Contact the research team at soree8826kim@gmail.com for enrollment information.
Where is the NCT04822649 trial being conducted?
This trial is being conducted at Seoul, South Korea.
Who is sponsoring the NCT04822649 clinical trial?
NCT04822649 is sponsored by Korea University Anam Hospital. The trial plans to enroll 100 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.